---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336762"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-08-06T11:35:16+00:00"
generated_at: "2026-08-06T11:40:31.855714+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Climb Bio Q2 2026 cash $239.2M; pipeline advances with CLYM116 Phase 2 initiation in Q3

## Summary
- Cash, cash equivalents, and marketable securities $239.2M as of June 30, 2026; raised ~$110M in private placement in April 2026, extending runway into H2 2028.
- R&D expenses $9.7M (vs $6.6M YoY); G&A $5.6M (vs $4.1M YoY); other income $1.9M.
- CLYM116 Phase 1 data to be presented at R&D Spotlight on Sept 3, 2026; Phase 2 trial in IgAN to start dosing in Q3 2026.
- Budoprutug data expected from pMN, ITP, and SLE studies in Q4 2026; SC formulation data positive.
- Appointed Breanna O'Reilly, Ph.D., to Board of Directors in June 2026.

## SEC filing metadata
- accession: 0001193125-26-336762
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-08-06T11:35:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/0001193125-26-336762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526336762/clym-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336762
- JSON: https://secwatch.observer/filing/0001193125-26-336762.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.